HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 701–800 of 1,001
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Fabbri, G., & Maggioni, A. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0025-6 · Cited by 20
Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia
Ali, Y. S., Linton, M. F., & Fazio, S. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f5ff98 · Cited by 20
Hayashi, R., Tamada, D., Murata, M., Kitamura, T., Mukai, K., Maeda, N., Otsuki, M., & Shimomura, I. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00420 · Cited by 17
Swiner, D. J., Kulyk, D. S., Osae, H., Durisek, G., & Badu-Tawiah, A. K. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03270 · Cited by 16
Manubolu, V. S., Verghese, D., Lakshmanan, S., Alalawi, L. H., Kinninger, A., Aldana-Bitar, J., Calicchio, F., Ahmad, K., Ghanem, A. K., Javier, D. A., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.003 · Cited by 17
Al‐Rasadi, K., Al-Zakwani, I., Zubaid, M., Ali, A., Bahnacy, Y., Sulaiman, K., Mahmeed, W. M. A., Suwaidi, J. A., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010203 · Cited by 22
Fiévet, C., & Staels, B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0043-5 · Cited by 19
Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA
Coca, A., Cea‐Calvo, L., Lozano, J. V., Inaraja, V., Fernández, C., Navarro, J., Bonet, Á., & Redón, J. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)72100-1 · Cited by 16
Negi, S., & Ballantyne, C. M. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.008 · Cited by 17
Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance
Mooradian, A. D., & Haas, M. J. (2015) · Drugs · doi:10.1007/s40265-015-0390-1 · Cited by 17
“Indeed, in clinical trials evaluating the efficacy of statins, the deleterious effect of low HDLc persists in those where the statins lowered the LDLc to target levels [6].”
BackgroundKumar, A., & Cannon, C. P. (2007) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2007.00298.x · Cited by 16
Manita, D., Hirowatari, Y., & Yoshida, H. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215584405 · Cited by 17
Leberkühne, L. J., Ebtehaj, S., Dimova, L. G., Dikkers, A., Dullaart, R. P. F., Bakker, S. J. L., & Tietge, U. J. F. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.04.008 · Cited by 18
Comparison of CVD Risk Associated With the Long Term Use of Contraceptives in Young Females
Jamil, S. (2012) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2012.21111 · Cited by 16
Hagström, E., Roe, M. T., Hafley, G. E., Neely, M. L., Sidhu, M. S., Winters, K. J., Prabhakaran, D., White, H. D., Armstrong, P. W., Fox, K. A. A., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22533 · Cited by 21
La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico
Millán, J., Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., González‐Santos, P., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.05.002 · Cited by 26
Primary genetic disorders affecting high density lipoprotein (HDL)
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212546 · Cited by 17
Suematsu, Y., Goto, M., Park, C., Nunes, A. C. F., Jing, W., Streja, E., Rhee, C. M., Cruz, S., Kashyap, M. L., Vaziri, N. D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00334 · Cited by 16
Neonatal HDL Counteracts Placental Vascular Inflammation via S1P–S1PR1 Axis
Gaudio, I. D., Hendrix, S., Christoffersen, C., & Wadsack, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030789 · Cited by 14
“High-density lipoproteins (HDLs) are potent anti-atherogenic mediators in adult human circulation due to their capability to remove cholesterol from peripheral tissues [5,6].”
BackgroundZhang, C., Wang, S., Li, M., & Wu, Y. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s246497 · Cited by 21
Lv, S., Song, Y., Zhang, F.-L., Yan, X., Chen, J., Gao, L., Guo, Z., & Yang, Y. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420953054 · Cited by 16
High-density lipoprotein cholesterol: How High
Sachan, A., Rajagopal, G. M., & Suresh, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104048 · Cited by 22
Shimizu, T., Tanigawa, H., Miura, S.-I., Kuwano, T., Takata, K., Suematsu, Y., Imaizumi, S., Yahiro, E., Zhang, B., Uehara, Y., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.012 · Cited by 16
Mean Platelet Volume is Elevated in Patients With Low High-Density Lipoprotein Cholesterol
Varol, E., Aksoy, F., Baş, H. A., Arı, H., & Özaydın, M. (2013) · Angiology · doi:10.1177/0003319713504024 · Cited by 16
Alenazi, A. M., Alshehri, M. M., Hoover, J. C., Yabroudi, M. A., Kachanathu, S. J., & Liu, W. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2017.0104 · Cited by 17
Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease
Badimón, J. J., & Ibáñez, B. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70065-7 · Cited by 20
How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD
Steiner, G. A. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6190-7 · Cited by 22
Lee, J.-G., Koh, S. J., Yoo, S. Y., Yu, J. R., Lee, S. A., Koh, G., & Lee, D. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.3.317 · Cited by 19
Puri, R., Nissen, S. E., Shao, M., Kataoka, Y., Uno, K., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315572920 · Cited by 17
Majeed, F., & Miller, M. J. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f79b0b · Cited by 17
Joseph, P. G., & Teo, K. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0190-5 · Cited by 14
How cholesteryl ester transfer protein can also be a potential triglyceride transporter
Chirasani, V. R., & Senapati, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05449-z · Cited by 14
Is microRNA-33 an Appropriate Target in the Treatment of Atherosclerosis?
Sidorkiewicz, M. (2023) · Nutrients · doi:10.3390/nu15040902 · Cited by 17
“The negative correlation between HDL concentration and the risk of cardiovascular diseases strongly suggests cardioprotective properties of HDL [9].”
BackgroundYang, Y., Shen, X.-Y., Tang, H., Liu, H., & Wen, Y. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.003 · Cited by 15
Simvastatin improves spinal fusion in rats
Bostan, B., Gunes, T., Aşçı, M., Sen, C., Kelestemur, M. H., Erdem, M., Koseoglu, R. D., & Erkorkmaz, Ü. (2011) · Acta Orthopaedica et Traumatologica Turcica · doi:10.3944/aott.2011.2526 · Cited by 15
Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution
Ferrières, J., Bérard, E., Crisan, O., & Bongard, V. (2010) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2010.04.003 · Cited by 15
Sazonov, V., Beetsch, J. W., Phatak, H. M., Wentworth, C., & Evans, M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.021 · Cited by 18
Al-Zakwani, I. S., Sulaiman, K., Al‐Rasadi, K., & Mikhailidis, D. P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.559537 · Cited by 15
The ezetimibe controversy: implications for clinical practice
Khanderia, U., Regal, R. E., Rubenfire, M., & Boyden, T. F. (2011) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944711410099 · Cited by 16
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL
Cao, P., Pan, H., Xiao, T., Zhou, T., Guo, J., & Su, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817245 · Cited by 16
Safety review of combination drugs for hyperlipidemia
Farnier, M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540237 · Cited by 15
The Application of the LDL Principle
Schade, D. S., Cavanaugh, B., Ramo, B. W., & Eaton, R. P. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.65012 · Cited by 16
“For example, statins (at least in higher dosages) raise HDL-c and part of their anti-atherosclerotic effects has been attributed to this activity [53] [122].”
Pharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
Chalcone Derivatives Enhance ATP-Binding Cassette Transporters A1 in Human THP-1 Macrophages
Teng, I.-J., Tsai, M., Shih, S.-F., Tsuei, B.-F., Chang, H. W., Chuang, Y., Lin, C., Chern, C., & Chen, S. (2018) · Molecules · doi:10.3390/molecules23071620 · Cited by 16
Zeng, N., Wang, A., Xu, T., Zhong, C., Zheng, X., Zhu, Z., Peng, Y., Peng, H. Y., Li, Q., Ju, Z., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.04.007 · Cited by 16
Framingham cardiovascular risk in patients with obesity and periodontitis
Pires, J. R., Santos, I. P., de Camargo, L., Zuza, E. P., de Toledo, B. E. C., & Monteiro, S. C. M. (2014) · Journal of Indian Society of Periodontology · doi:10.4103/0972-124x.128193 · Cited by 15
“[34] Persson and Persson, suggested that high serum levels of LDL and low levels of HDL are predictive of cardiovascular disease; thus, representing important risk factors for heart disease.”
Cardiovascular Disease Risk Factors Other than Dyslipidemia
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.17368 · Cited by 19
Mooradian, A. D., & Haas, M. J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0068-1 · Cited by 17
TaqIB and severity of coronary artery disease in the Turkish population: a pilot study
Kaman, D., İlhan, A., İlhan, N., & Akbulut, M. (2015) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2015.157 · Cited by 15
“Low HDL cholesterol is still predictive of high CVD risk in subjects with low LDL cholesterol [26].”
BackgroundPitavastatin: finding its place in therapy
Ose, L. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310389227 · Cited by 18
Rubel, R., Santa, H. S. D., Fernandes, L. C., Bonatto, S. J. R., Bello, S. R. D. B., de Figueiredo, B. C., Filho, J. H. C. L., Santos, C. A. D. M., & Soccol, C. R. (2010) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-010-0554-9 · Cited by 15
“The plasma lipid profile characterized by low HDL cholesterol and increased total cholesterol, LDL cholesterol, and triacylglycerol levels plays an important role in the development of atherosclerosis ( Barter et al. 2007 ).”
BackgroundDiplotyper: diplotype-based association analysis
Kim, S., Park, K., Shin, C., Cho, N. H., Ko, J., Koh, I., & Kwack, K. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-s2-s5 · Cited by 16
Importance of high-density lipoprotein quality: evidence from chronic kidney disease
Kon, V., Ikizler, T. A., & Fazio, S. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835fe47f · Cited by 15
Lipid metabolism in children and adolescents: Impact on vascular biology
Mietus‐Snyder, M., & Krauss, R. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.04.002 · Cited by 16
Gitt, A. K., Juenger, C., Jannowitz, C., Karmann, B., Senges, J., & Bestehorn, K. P. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832a4e25 · Cited by 17
Andrews, J., Puri, R., Kataoka, Y., Nicholls, S. J., & Psaltis, P. J. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.02 · Cited by 19
Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction
Lee, C. H., Woo, J. S., Park, C. B., Cho, J. M., Ahn, Y. K., Kim, C. J., Jeong, M. H., & Kim, W. (2016) · Medicine · doi:10.1097/md.0000000000003319 · Cited by 15
Lipoprotein (a) as an Acute Phase Reactant in Patients on Chronic Hemodialysis
TopciuShufta, V., Begolli, L., & Kryeziu, E. (2010) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2010.2728 · Cited by 15
When high is low: Raising low levels of high-density lipoprotein cholesterol
Toth, P. P. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0077-2 · Cited by 15
Jerzewski, K., Ruel, M., Voisine, P., May, M. L. L., & Kulik, A. (2013) · Journal of Cardiothoracic Surgery · doi:10.1186/1749-8090-8-172 · Cited by 17
Zhao, J., Yan, H., Li, Y., Wang, J., Han, L., Wang, Z., Tang, M., Zhang, W., Zhang, Y., & Zhong, M. (2015) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400181 · Cited by 15
Polonsky, T. S., & Davidson, M. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.051 · Cited by 16
Dullaart, R. P. F. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.209544 · Cited by 14
Arutyunov, G. P., Boytsov, S. A., Voyevoda, M. I., Gurevich, V. S., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Sergiyenko, I. V., Shestakova, M. V., Aliyeva, A. S., et al. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-2-282-288 · Cited by 20
High-Density Lipoprotein Therapy: Is There Hope?
Bhatt, K., Wells, B. J., Sperling, L. S., & Baer, J. (2010) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-010-0081-x · Cited by 15
“& Niacin was the first lipid-modifying agent shown to have an effect on cardiovascular end points [ 8 ].”
BackgroundAgongo, G., Raal, F. J., Nonterah, E. A., Debpuur, C. Y., Oduro, A. R., Ramsay, M., & Crowther, N. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278375 · Cited by 15
“In the unadjusted models only non-HDL-C (Table 3, model 5) and LDL-C/HDL-C (Table 3, model 7) were significantly (P = 0.01 and P = 0.02, respectively) associated with CVD.”
BackgroundInfluentialLorin, J., Guilland, J.-C., Korandji, C., Touzery, C., Bichât, F., Chagnon, A., Cottin, Y., Rochette, L., Vergely, C., & Zeller, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064796 · Cited by 20
Bishop, B. M. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828b8463 · Cited by 18
Emerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista
Ascaso, J. F., & Carmena, R. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.07.002 · Cited by 26
Negi, P., Lövgren, J., Malmi, P., Sirkka, N., Metso, J., Huovinen, T., Brockmann, E., Pettersson, K. S. I., Jauhiainen, M., & Lamminmäki, U. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.11.020 · Cited by 14
Eberhart, T., Eigner, K., Filik, Y., Fruhwürth, S., Stangl, H., & Röhrl, C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.110 · Cited by 14
Arslan, E., Can, S., & Demirkan, E. (2017) · Science & Sports · doi:10.1016/j.scispo.2016.11.004 · Cited by 19
Endo, H., Dohi, T., Miyauchi, K., Kuramitsu, S., Kato, Y., Okai, I., Yokoyama, M. N., Yokoyama, T., Andò, K., Okazaki, S., et al. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.12.023 · Cited by 13
Kopčeková, J., Kolesárová, A., Schwarzová, M., Kováčik, A., Mrázová, J., Gažarová, M., Lenártová, P., Chlebo, P., & Kolesárová, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020857 · Cited by 15
Nicholls, S. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0252-3 · Cited by 15
HDL and Cholesterol Ester Transfer Protein (CETP)
Deng, S., Liu, J., & Niu, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_2 · Cited by 17
McDonough, C. W., Gillis, N., Alsultan, A., Chang, S.-W., Kawaguchi‐Suzuki, M., Lang, J. E., Shahin, M. H., Buford, T. W., Rouby, N. M. E., Sá, A. C. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076984 · Cited by 14
Role of Propolis in Improving Hepatic and Renal Damage in Boldenone Undecylenate in Male Rats
Barakat, L. A. A., Tousson, E., Ibrahim, W., & El-Hakeem, A. A. (2015) · Cited by 14
Schwartz, G. G. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.019 · Cited by 16
Fibrates in CVD: a step towards personalised medicine
Staels, B. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60758-1 · Cited by 17
HDL functionality in South Asians as compared to white Caucasians
Bakker, L. E. H., Boon, M. R., Annema, W., Dikkers, A., van Eyk, H. J., Verhoeven, A., Mayboroda, O. A., Jukema, J. W., Havekes, L. M., Meinders, A. E., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.010 · Cited by 16
Ding, X., Lv, Y., Miao, L., Yan, L., Chen, Q.-F., & Shi, Z. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96199 · Cited by 14
“Such a phenomenon may be due to the anti-inflammatory and antioxidant properties 33–35 of HDL-C.”
Liu, H., Guo, Y., Wu, N., Zhu, C., Gao, Y., Qing, P., Li, S., Zhao, X., Zhang, Y., Sun, D., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.013 · Cited by 14
Akindele, A. J., Oladimeji-Salami, J. A., Oyetola, R. A., & Osiagwu, D. D. (2018) · Medicines · doi:10.3390/medicines5010004 · Cited by 14
Kobayashi, D., Noto, H., Shimbo, T., Ino, T., Osugi, Y., Takahashi, O., & Asai, K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.918 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Orsi, E., Penno, G., Solini, A., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Morano, S., Baroni, M. G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01224-7 · Cited by 16
Huang, X., Su, J., Rao, A. U., Tang, H., Zhou, W. J., Zhu, X., Chen, X., Liu, Z., Huang, Y., Degrado, S. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.041 · Cited by 14
Rizzo, M., Berneis, K. K., Spinas, G. A., Rini, G. B., & Kapur, N. K. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01979.x · Cited by 14
Simone, R. D. (1994) · Springer eBooks · doi:10.1007/978-3-642-78956-4_5 · Cited by 14
Polonsky, T. S., Mazzone, T., & Davidson, M. H. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.06.002 · Cited by 14
Esmaeili, P., Roshanravan, N., Ghaffari, S., Alamdari, N. M., & Jafarabadi, M. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-55141-2 · Cited by 15
Complete Apo AI Deficiency in an Iraqi Mandaean Family: Case studies and review of the literature
Al-Sarraf, A. J., Alghofaili, K., SULLIVAN, D. R., Wasan, K. M., Hegele, R. A., & Frohlich, J. J. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.05.001 · Cited by 13
Farnier, M., Ducobu, J., & Bryniarski, L. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.626398 · Cited by 14
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future
Hajhosseiny, R., Sabir, I. N., Khavandi, K., & Wierzbicki, A. S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.76 · Cited by 14
Xiang, W., Hu, Z., He, X., & Dang, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.042 · Cited by 13
Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.007 · Cited by 17
Mayne, T. J., Nordyke, R. J., Schold, J. D., Weir, M. R., & Mohan, S. (2021) · Clinical Transplantation · doi:10.1111/ctr.14326 · Cited by 17
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.